Emergence of cryptococcal disease: Epidemiologic perspectives 100 years after its discovery

Epidemiologic Reviews

Volumn 17, Issue 2, 1995, Pages 303-320

  Hajjeh, Rana A ^a   Brandt, Mary E ^a   Pinner, Robert W ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CLINICAL FEATURE; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DNA PROBE; ELECTROPHORESIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION; KARYOTYPING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SEROLOGY; SKIN TEST;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; CRYPTOCOCCOSIS; CRYPTOCOCCUS; DIAGNOSIS, DIFFERENTIAL; DNA PROBES; ELECTROPHORESIS; FEMALE; HUMANS; INCIDENCE; KARYOTYPING; MALE; POLYMERASE CHAIN REACTION; RISK FACTORS; SEX DISTRIBUTION;

EID: 0029554917     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.epirev.a036195     Document Type: Article

References (203)

1. Busse O. Uber parasitare zelleinschlusse und ihre zuchtung. (In German). Zentralbl Bakteriol 1894;16:175-80.
2. Sanfelice F. Contribute) all morfologia e biologia dei blas- tomicetei ehe si sviluppano nei succhi di alcuni frutti. (In Italian). Ann Ig Sperimentale 1894;4:463-95.
3. Kreger-van Rij NJW, ed. The yeasts: a taxonomic study. 3rd Epidemiol Rev Vol. 17, No. 2, 1995
4. Kwon-Chung KJ. A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia 1975;67: 1197-200.
5. Ikeda R, Shinoda T, Fukazawa Y, et al. Antigenic character-ization of Cryptococcus neoformans serotypes and its appli-cation to serotyping of clinical isolates. J Clin Microbiol 1982;16:22-9.
6. Bottone EJ, Toma M, Johansson BE, et al. Poorly encapsu¬lated Cryptococcus neoformans from patients with AIDS. I. Preliminary observations. AIDS Res 1986;2:211-18.
7. Bottone EJ, Wormser GP. Poorly encapsulated Cryptococcus neoformans from patients with AIDS.?. Correlation of cap-sule size observed directly in cerebrospinal fluid with that after animal passage. AIDS Res 1986;2:219-25.
8. Patterson TF, Andriole VT. Current concepts in cryptococ-cosis. Eur J Clin Microbiol Infect Dis 1989;8:457-65.
9. Bulmer GS, Sans MD, Gunn CM. Cryptococcus neoformans. I. Nonencapsulated mutants. J Bacteriol 1967;94:1475-9.
10. Bhattacharjee AK, Kwon-Chung KJ, Glaudemans CPJ. The major capsular polysaccharide of Cryptococcus neoformans serotype B. Carbohydr Res 1992;233:271-2.
11. da Cunha T, Lusins J. Cryptococcus albidus meningitis. South Med J 1973;66:1230, passim.
12. Gluck JL, Myers JP, Pass LM. Cryptococcemia due to Cryp-tococcus albidus. South Med J 1987;80:511-13.
13. Melo JC, Srinivasan S, Scott ML, et al. Cryptococcus albidus meningitis. J Infect 1980;2:79-82.
14. Kamalam A, Yesudian P, Thambiah AS. Cutaneous infection by Cryptococcus laurentii. Br J Dermatol 1977;97:221-3.
15. Lynch JP 3d, Schaberg DR, Kissner DG, et al. Cryptococcus laurentii lung abscess. Am Rev Respir Dis 1981;123:135-8.
16. Binder L, Csillag A, Toth G. Diffuse infiltration of the lungs associated with Cryptococcus luteolus. Lancet 1956;2: 1043-5.
17. Krajden S, Summerbell RC, Kane J, et al. Normally saprobic cryptococci isolated from Cryptococcus neoformans infections. J Clin Microbiol 1991;29:1883-7.
18. Emmons CW. Isolation of Cryptococcus neoformans from soil. J Bacteriol 1951;62:685-90.
19. Emmons C. The significance of saprophytism in the epide-miology of the mycoses. Trans N Y Acad Sei 1954;17(series U): 157-66.
20. Emmons CW. Saprophytic sources of Cryptococcus neofor¬mans associated with the pigeon (Columba livia). Am J Hyg 1955;62:227-32.
21. Kao CJ, Schwarz J. The isolation of Cryptococcus neofor-mans from pigeon nests. Am J Clin Pathol 1957;27:652-3.
22. Ajello L. Occurrence of Cryptococcus neoformans in soils. Am J Hyg 1958;67:72-7.
23. Emmons CW. Prevalence of Cryptococcus neoformans in pigeon habitats. Public Health Rep 1960;75:362-4.
24. Littman ML, Schneierson SS. Cryptococcus neoformans in pigeon excreta in New York City. Am J Hyg 1959;69:49-59.
25. Muchmore HG, Rhoades ER, Nix GE, et al. Occurrence of Cryptococcus neoformans in the environment of three geo-graphically associated cases of cryptococcal meningitis. N Engl J Med 1963;268:1112-14.
26. Procknow JJ, Benfield JR, Rippon JW. Cryptococcal hepa-titis presenting as a surgical emergency. JAMA 1965; 191: 269-74.
27. White PD Jr, Kaufman L, Weeks RJ. Cryptococcal meningitis: a case report and epidemiological study. J Med Assoc Ga 1982;71:539-42.
28. Denton JF, Di Salvo AF. The prevalence of Cryptococcus neoformans in various natural habitats. Sabouraudia 1968;6: 213-17.
29. Rosemberg S, Lopes MBS, Tsanaclis AM. Neuropathology of acquired immunodeficiency syndrome (AIDS): analysis of 22 Brazilian cases. J Neurol Sei 1986;76:187-98.
30. Ruiz A, Velez D, Fromtling R. Isolation of saprophytic Cryptococcus neoformans from Puerto Rico: distribution and variety. Mycopathologia 1989;106:167-70.
31. St-Germain G, Auger P, Lemieux C. Cryptococcus neofor¬mans in Quebec (1985-1986). Mycoses 1988;31:123-8.
32. Lo D. Cryptococcosis in the Northern Territory. Med J Aust 1976;2:825-8.
33. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neo¬formans var. gattii. J Clin Microbiol 1990;28:1642-4.
34. Taylor RL, Duangmani C. Occurrence of Cryptococcus neo-formans in Thailand. Am J Epidemiol 1968;87:318-22.
35. Gugnani HC, Gupta NP, Shrivastav JB. Prevalence of Cryp-tococcus neoformans in Delhi Zoological Park and its recov-ery from the sputum of an employee. Indian J Med Res 1972;60:182-5.
36. Pal M. Cryptococcus neoformans var. neoformans and munia birds. Mycoses 1989;32:250-2.
37. Sotgiu G, Mazzoni A, Mantovani A, et al. Survey of soils for human pathogenic fungi from the Emilia-Romagna region of Italy.?. Isolation of Allescheria boydii, Cryptococcus neo-formans, and Histoplasma capsulatum. Am J Epidemiol 1966;83:329-37.
38. Staib F. Pathogenic fungi in human dwellings. Mycoses 1992;35:289-92.
39. Bauwens L, Swinne D, De Vroey CH, et al. Isolation of Cryptococcus neoformans var. neoformans in the aviaries of the Antwerp Zoological Gardens. Mykosen 1986;29:291-4.
40. Swinne-Desgain D. Cryptococcus neoformans of saprophytic origin. Sabouraudia 1975;13:303-8.
41. Bulmer GS. Twenty-five years with Cryptococcus neofor-mans. Mycopathologia 1990;109:111-22.
42. Kwon-Chung KJ, Varma A, Howard DH. Ecology of Cryp-tococcus neoformans and prevalence of its two varieties in AIDS and non-AIDS associated cryptococcosis. In: van den Bossche H, Mackenzie DWR, Cauwenbergh G, et al, eds. Mycoses in AIDS patients. New York, NY: Plenum Press, 1990:103-13.
43. Staib F. New concepts in the occurrence and identification of Cryptococcus neoformans. Mycopathol Mycol Appl 1963; 19:143-5.
44. Ruiz A, Fromtling RA, Bulmer GS. Distribution of Crypto-coccus neoformans in a natural site. Infect Immun 1981;31: 560-3.
45. Ishaq CM, Bulmer GS, Felton FG. An evaluation of various environmental factors affecting the propagation of Crypto-coccus neoformans. Mycopathol Mycol Appl 1968;35: 81-90.
46. Ruiz A, Neilson JB, Bulmer GS. Control of Cryptococcus neoformans in nature by biotic factors. Sabouraudia 1982; 20:21-9.
47. Littman ML, Borok R, Dalton TJ. Experimental avian cryp-tococcosis. Am J Epidemiol 1965;82:197-207.
48. Littman ML, Borok R. Relation of the pigeon to cryptococcosis: natural carrier state, heat resistance, and sur¬vival of Cryptococcus neoformans. Mycopathol Mycol Appl 1968;35:329-45.
49. Felton FG, Muchmore HG, McCarty MA. Epidemiology of cryptococcosis. I. Environmental distribution of cryptococci in Oklahoma. Health Lab Sei 1974;11:201-4.
50. Gordon MA. The epidemiology of cryptococcosis. In: Al- Doory Y, ed. The epidemiology of human mycotic diseases. Springfield, IL: Charles C Thomas, 1975:142-51.
51. Pounden WD, Amberson JM, Jaeger AB. A severe mastitis problem associated with Cryptococcus neoformans in a large dairy herd. Am J Vet Res 1952;13:121-8.
52. Pal M, Mehrotra BS. Studies of the isolation of Cryptococcus neoformans from fruits and vegetables. Mykosen 1985;28: 200-5.
53. Klein E. Pathogenic microbes in milk. J Hyg 1901;1:78-95.
54. Carter HS, Young JL. Note on the isolation of Cryptococcus neoformans from a sample of milk. J Pathol Bacteriol 1950; 62:271-3.
55. Cobcroft R, Kronenberg H, Wilkinson T. Cryptococcus in bagpipes. (Letter). Lancet 1978;1:1368-9.
56. Pfeiffer T, Ellis D. Environmental isolation of Cryptococcus neoformans gattii from California. (Letter). J Infect Dis 1991;163:929-30.
57. Pfeiffer TJ, Ellis DH. Environmental isolation of Cryptococ¬cus neoformans var. gattii from Eucalyptus tereticomis. J Med Vet Mycol 1992;30:407-8.
58. Ellis DH, Pfeiffer TJ. Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet 1990;336: 923-5.
59. Kwon-Chung KJ, Wiekes BL, Stockman L, et al. Virulence, serotype, and molecular characteristics of environmental strains of Cryptococcus neoformans var. gattii. Infect Immun 1992;60:1869-74.
60. Cohen J, Perfect JR, Durack DT. Cryptococcosis and the basidiospore. (Letter). Lancet 1982; 1:1301.
61. Stenderup A. Ecology of yeast and epidemiology of yeast infections. Acta Derm Venereol Suppl (Stockh) 1986; 121: 27-37.
62. Howard DH. The commensalism of Cryptococcus neofor¬mans. Sabouraudia 1973;11:171-4.
63. Randhawa HS, Paliwal DK. Occurrence and significance of Cryptococcus neoformans in the oropharynx and on the skin of a healthy human population. J Clin Microbiol 1977;6: 325-7.
64. Hammerman KJ, Powell KE, Christianson CS. Pulmonary cryptococcosis: clinical forms and treatment. A Center for Disease Control cooperative mycoses study. Am Rev Respir Dis 1973;108:1116-23.
65. Haugen RK, Baker RD. The pulmonary lesions in crypto-coccosis with special reference to subpleural nodules. Am J Clin Pathol 1954;24:1381-90.
66. McDonnell JM, Hutchins GM. Pulmonary cryptococcosis. Hum Pathol 1985;16:121-8.
67. Neilson JB, Fromtling RA, Bulmer GS. Cryptococcus neoformans: size range of infectious particles from aerosol-ized soil. Infect Immun 1977;17:634-8.
68. Powell KE, Dahl BA, Weeks RJ, et al. Airborne Cryptococ-cus neoformans: particles from pigeon excreta compatible with alveolar deposition. J Infect Dis 1972;125:412-15.
69. Farhi F, Bulmer GS, Tacker JR. Cryptococcus neoformans. IV. The not-so-encapsulated yeast. Infect Immun 1970; 1: 526-31.
70. Ellis D, Pfeiffer T. The ecology of Cryptococcus neofor-mans. Eur J Epidemiol 1992;8:321-5.
71. Takos MJ. Experimental cryptococcosis produced by the ingestion of virulent organisms. N Engl J Med 1956;254: 598-601.
72. Beyt BE Jr, Waltman SR. Cryptococcal endophthalmitis after corneal transplantation. N Engl J Med 1978;298:825-6.
73. Glaser JB, Garden A. Inoculation of cryptococcosis without transmission of the acquired immunodeficiency syndrome. (Letter). N Engl J Med 1985;313:266.
74. Kwon-Chung KJ, Bennett JE. Medical mycology. Philadel-phia, PA: Lea and Febiger, 1992.
75. Diamond RD. Cryptococcus neoformans. In: Mandell GL, Douglas RG Jr, Bennett JE, eds. Principles and practice of infectious diseases. New York, NY: Churchill Livingstone, 1980.
76. Chemik NL, Armstrong D, Posner JB. Central nervous sys¬tem infections in patients with cancer. Medicine 1973;52: 563-81.
77. Kovacs JA, Kovacs AA, Polis M, et.al. Cryptococcosis in the acquired immunodeficiency syndrome. Ann Intern Med 1985;103:533-8.
78. Agranat O, Melmed S, Altmann G, et al. Bacterial and fungal meningitis in adults: a 22-year survey in a large community hospital in Israel. Isr J Med Sei 1977;13:1151-62.
79. White MH, Armstrong D. Cryptococcosis. Infect Dis Clin North Am 1994;8:383-98.
80. Kerkering TM, Duma RJ, Shadomy S. The evolution of pulmonary cryptococcosis: clinical implications from a study of 41 patients with and without compromising host factors. Ann Intern Med 1981;94:611-16.
81. Allende M, Pizzo PA, Horowitz M, et al. Pulmonary cryp-tococcosis presenting as métastasés in children with sarco-mas. Pediatr Infect Dis J 1993;12:240-3.
82. Campbell GD. Primary pulmonary cryptococcosis. Am Rev Respir Dis 1966;94:236-43.
83. Hernandez AD. Cutaneous cryptococcosis. Dermatol Clin 1989;7:269-74.
84. Nottebart HC, McGehee RF, Utz JP. Cryptococcus neofor¬mans osteomyelitis: case report of two patients. Sabouraudia 1974;12:127-32.
85. Behrman RE, Masci JR, Nicholas P. Cryptococcal skeletal infections: case report and review. Rev Infect Dis 1990; 12: 181-90.
86. Diamond RD, Bennett JE. Prognostic factors in cryptococcal meningitis: a study in 111 cases. Ann Intern Med 1974;80: 176-81.
87. Chuck SL, Sande MA. Infections with Cryptococcus neofor-mans in the acquired immunodeficiency syndrome. N Engl J Med 1989;321:794-9.
88. Horsburgh CR, Selik RM. Extrapulmonary cryptococcosis in AIDS patients: risk factors and association with decreased survival. (Abstract). Presented at the 28th Interscience Con¬ference on Antimicrobial Agents and Chemotherapy, Los Angeles, California, October 1988.
89. Vandepitte J. Clinical aspects of cryptococcosis in patients with AIDS. In: van den Bossche H, Mackenzie DWR, Cauwenbergh G, et al, eds. Mycoses in AIDS patients. New York, NY: Plenum Press, 1990:115-22.
90. Panther LA, Sande MA. Cryptococcal meningitis in the acquired immunodeficiency syndrome. Semin Respir Infect 1990;5:138-45.
91. Dismukes WE. Cryptococcal meningitis in patients with AIDS. J Infect Dis 1988;157:624-8.
92. Eng RHK, Bishburg E, Smith SM, et al. Cryptococcal infec-tions in patients with acquired immune deficiency syndrome. Am J Med 1986;81:19-23.
93. Grant IH, Armstrong D. Fungal infections in AIDS: crypto-coccosis. Infect Dis Clin North Am 1988;2:457-64.
94. Zuger A, Louie E, Holzman RS, et al. Cryptococcal disease in patients with the acquired immunodeficiency syndrome: diagnostic features and outcome of treatment. Ann Intern Med 1986;104:234-40.
95. Ricciardi DD, Sepkowitz DV, Berkowitz LB, et al. Crypto-coccal arthritis in a patient with acquired immune deficiency syndrome: case report and review of the literature. J Rheu¬matol 1986;13:455-8.
96. Denning DW, Armstrong RW, Fishman M, et al. Endoph-thalmitis in a patient with disseminated cryptococcosis and AIDS who was treated with itraconazole. Rev Infect Dis 1991;13:1126-30.
97. White M, Cirrincione C, Blevins A, et al. Cryptococcal meningitis: outcome in patients with AIDS and patients with neoplastic disease. J Infect Dis 1992;165:960-3.
98. Larsen RA, Bozzette S, McCutchan JA, et al. Persistent Cryptococcus neoformans infection of the prostate after suc-cessful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med 1989; 111:125-8.
99. Bailly MP, Boibieux A, Biron F, et al. Persistence of Cryp¬tococcus neoformans in the prostate: failure of fluconazole despite high doses. (Letter). J Infect Dis 1991;164:435-6.
100. Clark RA, Greer D, Atkinson W, et al. Spectrum of Crypto-coccus neoformans infection in 68 patients infected with human immunodeficiency virus. Rev Infect Dis 1990; 12: 768-77.
101. Saag MS, Powderly WG, Cloud GA. Comparison of ampho-tericin B with fluconazole in the treatment of acute AIDS- associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992;326:83-9.
102. Powderly WG. Therapy for cryptococcal meningitis in pa-tients with AIDS. Clin Infect Dis 1992;14(suppl l):S54-9.
103. Bennett JE, Bailey JW. Control for rheumatoid factor in the latex test for cryptococcosis. Am J Clin Pathol 1971;56: 360-5.
104. McManus EJ, Jones JM. Detection of a Trichosporon beigelii antigen cross-reactive with Cryptococcus neoformans capsu¬lar polysaccharide in serum from a patient with disseminated Trichosporon infection. J Clin Microbiol 1985;21:681-5.
105. Kaufman L, Blumer S. Value and interpretation of serolog-ical tests for the diagnosis of cryptococcosis. Appl Microbiol 1968;16:1907-12.
106. Goodman JS, Kaufman L, Koenig MG. Diagnosis of cryp-tococcal meningitis: value of immunologic detection of cryp-tococcal antigen. N Engl J Med 1971;285:434-6.
107. Powderly WG, Cloud GA, Dismukes WE, et al. Measure¬ment of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated crypto¬coccal meningitis. Clin Infect Dis 1994;18:789-92.
108. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 1979; 301:126-31.
109. Powderly WG, Saag MS, Cloud GA, et al. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryp-tococcal meningitis in patients with the acquired immunode-ficiency syndrome. The NIAID AIDS Clinical Trials Group and Mycoses Study Group. N Engl J Med 1992;326:793-8.
110. Bozzette SA, Larsen RA, Chiu J, et al. A placebo-controlled trial of maintenance therapy with fluconazole after treatment of cryptococcal meningitis in the acquired immunodeficiency syndrome. California Collaborative Treatment Group. N Engl J Med 1991;324:580-4.
111. Boken DJ, Swindells S, Rinaldi MG. Fluconazole-resistant Candida albicans. Clin Infect Dis 1993;17:1018-21.
112. Pfaller MA, Rhine-Chalberg J, Redding SW, et al. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis. J Clin Microbiol 1994;32:59-64.
113. Gustafson TL, Kaufman L, Weeks R, et al. Outbreak of acute pulmonary histoplasmosis in members of a wagon train. Am J Med 1981;71:759-65.
114. Dodge HJ. The association of a bird roosting with infection of school children by Histoplasma capsulatum. Am J Public Health 1965;55:1203-11.
115. Werner SB, Pappagianis D, Heindl I, et al. An epidemic of coccidioidomycosis among archeology students in northern California. N Engl J Med 1972;286:507-12.
116. Littman ML, Zimmerman LE. Cryptococcosis, torulosis, or European blastomycosis. New York, NY: Grune and Strat¬ton, 1956.
117. Centers for Disease Control and Prevention. HIV/AIDS sur-veillance. Atlanta, GA: Centers for Disease Control and Prevention, 1992.
118. Pinner RW, Hutwagner L, Collin SF. Use of hospital dis-charge data to describe recent changes in the epidemiology of cryptococcal disease. (Abstract). Presented at the 31st Interscience Conference on Antimicrobial Agents and Chemo-therapy, Chicago, Illinois, September 1991.
119. Pinner RW, Shihata N, Anderson G. Population-based active surveillance for ciyptococcal disease. (Abstract). Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 1993.
120. Jackson LA, Wenger JD. Laboratory-based surveillance for meningococcal disease in selected areas, United States, 1989-1991. MMWR CDC Surveill Summ 1993;42:21-30.
121. Rippon JW. Medical mycology: the pathogenic fungi and the pathogenic actinomycetes. 3rd ed. Philadelphia, PA: WB Saunders Company, 1988.
122. Crowe SM, Carlin JB, Stewart KI, et al. Predictive value of CD4 lymphocyte numbers for the development of opportu-nistic infections and malignancies in HIV-infected persons. J Acquir Immune Defic Syndr 1991;4:770-6.
123. Nightingale SD, Cal SX, Peterson DM, et al. Primary prophylaxis with fluconazole against systemic fungal infections in HIV-positive patients. AIDS 1992;6:191-4.
124. Littman ML, Walter JE. Cryptococcosis: current status. Am J Med 1968;45:922-32.
125. Collins VP, Gellhom A, Trimble JR. The coincidence of cryptococcosis and disease of the reticuloendothelial and lymphatic systems. Cancer 1951;4:883-9.
126. Diamond RD, Bennett JE. Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans. J Infect Dis 1973;127:694-7.
127. Swinne D, Nkurikiyinfura JB, Muyembe TL. Clinical iso-lates of Cryptococcus neoformans from Zaire. Eur J Clin Microbiol Infect Dis 1986;5:50-1.
128. Lewis JL, Rabinovich S. The wide spectrum of cryptococcal infections. Am J Med 1972;53:315-22.
129. Gelfand M. Cryptococcal meningitis: report of two cases. Cent Afr J Med 1972;18:248-50.
130. Schroter GPJ, Hoelscher M, Putnam CW, et al. Fungus infections after liver transplantation. Ann Surg 1977; 186: 115-22.
131. Schroter GPJ, Temple DR, Husberg BS, et al. Cryptococco-sis after renal transplantation: report of ten cases. Surgery 1976;79:268-77.
132. Graybill JR, Alford RH. Cell-mediated immunity in crypto-coccosis. Cell Immunol 1974;14:12-21.
133. Henderson DK, Kan VL, Bennett JE. Tolerance to crypto-coccal polysaccharide in cured cryptococcosis patients: failure of antibody secretion in vitro. Clin Exp Immunol 1986; 65:639-46.
134. Krick JA. Familial cryptococcal meningitis. (Letter). J Infect Dis 1981; 143:133.
135. Smith DK, Neal JJ, Holmberg SD, et al. Unexplained oppor-tunistic infections and CD4+ T-lymphocytopenia without HIV infection: an investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-Lym- phocytopenia Task Force. N Engl J Med 1993;328:373-9.
136. Ho DD, Cao Y, Zhu T, et al. Idiopathic CD4+ T-lym- phocytopenia: immunodeficiency without evidence of HIV infection. N Engl J Med 1993;328:380-5.
137. Duncan RA, von Reyn CF, Alliegro GM, et al. Idiopathic CD4+ T-lymphocytopenia: four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med 1993;328:393-8.
138. Pizzo PA, Eddy J, Faloon J. Acquired immune deficiency syndrome in children: current problems and therapeutic con-siderations. Am J Med 1988;85(suppl 2): 195-202.
139. Leggiadro RJ, Barrett FF, Hughes WT. Extrapulmonary cryptococcosis in immunocompromised infants and children. Pediatr Infect Dis J 1992;11:43-7.
140. Leggiadro RJ, Mine MW, Hughes WT. Extrapulmonary cryptococcosis in children with acquired immunodeficiency syndrome. Pediatr Infect Dis J 1991;10:658-62.
141. Edwards VE, Sutherland JM, Tyrer JH. Cryptococcosis of the central nervous system: epidemiological, clinical, and therapeutic factors. J Neurol Neurosurg Psychiatry 1970;33: 415-25.
142. Restrepo A, Salazar ME, Cano LE, et al. Estrogens inhibit mycelium-to-yeast transformation in the fungus Paracoccid-ioides brasiliensis: implications for resistance of females to paracoccidioidomycosis. Infect Immun 1984;46:346-53.
143. Castro KG, Selik RM, Jaffe HW. Frequency of opportunistic diseases in AIDS patients, by race, ethnicity, and HIV trans¬mission categories—United States. (Abstract). Presented at the 28th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, October 1988.
144. Drutz DJ, Catanzaro A. Coccidioidomycosis. Part?. Am Rev Respir Dis 1978;117:727-71.
145. Kwon-Chung KJ, Bennett JE. Epidemiologic differences be-tween the two varieties of Cryptococcus neoformans. Am J Epidemiol 1984;120:123-30.
146. Bennett JE, Kwon-Chung KJ, Howard DH. Epidemiologic differences among serotypes of Cryptococcus neoformans. Epidemiol Rev Vol. 17, No. 2, 1995
147. Muchmore HG, Scott EN, Felton FG, et al. Cryptococcus neoformans serotype groups encountered in Oklahoma. Am J Epidemiol 1980;112:32-8.
148. Walter JE, Atchison RW. Epidemiological and immunolog¬ical studies of Cryptococcus neoformans. J Bacteriol 1966; 92:82-7.
149. Fink JN, Barboriak JJ, Kaufman L. Cryptococcal antibodies in pigeon breeders’ disease. J Allergy 1968;41:297-301.
150. Fessel WJ. Cryptococcal meningitis after unusual exposures to birds. (Letter). N Engl J Med 1993;328:1354-5.
151. Forthal D, Gordon R, Larsen R. Cigarette smoking increases the risk of developing cryptococcal meningitis. (Abstract). Presented at the VUI International Conference on AIDS, Amsterdam, The Netherlands, July 1992.
152. Edwards PQ, Palmer CD. Prevalence of sensitivity to coc- cidioidin, with special reference to specific and non-specific reactions to coccidioidin and histoplasmin. Dis Chest 1957; 31:35-60.
153. Bennett JE, Hasenclever HF. Evaluation of a skin test for cryptococcosis. Am Rev Respir Dis 1965;91:616.
154. Newbeny WM Jr, Walter JE, Chandler JW Jr, et al. Epide-miologic study of Cryptococcus neoformans. Ann Intern Med 1967;67:724-32.
155. Atkinson AJ Jr, Bennett JE. Experience with a new skin test antigen prepared from Cryptococcus neoformans. Am Rev Respir Dis 1968;97:637-43.
156. Vogel RA, Sellers TF, Woodward P. Fluorescent antibody techniques applied to the study of human cryptococcosis. JAMA 1961;178:153-5.
157. Kaufman L, Blumer S. Cryptococcosis: the awakening giant. In: Proceedings of the Fourth International Conference on the Mycoses, Brasilia, Brazil, June 1977. Washington, DC: Pan American Health Organization, 1977. (PAHO Scientific Pub¬lication no. 356)
158. Dromer F, Ronin O, Dupont B. Isolation of Cryptococcus neoformans var. gattii from an Asian patient in France: evidence for dormant infection in healthy subjects. J Med Vet Mycol 1992;30:395-7.
159. Bottone EJ, Kirschner PA, Salkin IF. Isolation of highly encapsulated Cryptococcus neoformans serotype B from a patient in New York City. J Clin Microbiol 1986;23:186-8.
160. Felton FG, Muchmore HG, McCarty MA. Epidemiology of cryptococcosis. II. Evaluation of patients’ environment. Health Lab Sei 1974;11:205-9.
161. Swinne D, Deppner M, Laroche R, et al. Isolation of Cryp-tococcus neoformans from houses of AIDS-associated cryp-tococcosis patients in Bujumbura (Burundi). AIDS 1989;3: 389-90.
162. Bottone EJ, Salkin IF, Hurd NJ, et al. Serogroup distribution of Cryptococcus neoformans in patients with AIDS. J Infect Dis 1987; 156:242.
163. Rinaldi MG, Drutz DJ, Howell A, et al. Serotypes of Cryp-tococcus neoformans in patients with AIDS. (Letter). J Infect Dis 1986; 153:642.
164. Shimizu RY, Howard DH, Clancy MN. The variety of Cryp-tococcus neoformans in patients with AIDS. (Letter). J Infect Dis 1986;154:1042.
165. Rozenbaum R, Goncalves AJ, Wanke B, et al. Cryptococcus neoformans varieties as agents of cryptococcosis in Brazil. Mycopathologia 1992;119:133-6.
166. Kapend’a K, Komichelo K, Swinne D, et al. Meningitis due to Cryptococcus neoformans biovar gattii in a Zairean AIDS patient. (Letter). Eur J Clin Microbiol 1987;6:320-1.
167. Rozenbaum R, Goncalves AJR, Wanke B, et al. Cryptococ¬cus neoformans var. gattii in a Brazilian AIDS patient. My-copathologia 1990;112:33-4.
168. Clancy MN, Fleishmann J, Howard DH, et al. Isolation of Cryptococcus neoformans gattii from a patient with AIDS in Southern California. (Letter). J Infect Dis 1990;161:809.
169. Henderson DK, Edwards JE, Dismukes WE, et al. Meningitis produced by different serotypes of Cryptococcus neoformans. (Abstract). Presented at the 81st Meeting of the Amer-ican Society for Microbiology, Dallas, Texas, May 1981.
170. Fromtling RA, Abruzzo GK, Ruiz A. Virulence and antifun-gal susceptibility of environmental and clinical isolates of Cryptococcus neoformans from Puerto Rico. Mycopatholo¬gia 1989;106:163-6.
171. Pinner RW, Hajjeh RA, Powderly WG. Prospects for the prevention of cryptococcosis in persons infected with human immunodeficiency virus. Clin Infect Dis 1995;21(suppl 1): S103-7.
172. Caputi R, Marston B, Siegel B, et al. Use of azole drugs to prevent cryptococcal infection in patients with AIDS. (Abstract). Presented at the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 1993
173. Newton JA, Olson P, Tasker SA, et al. Weekly fluconazole for the suppression of oral thrush in HIV seropositive patients: impact on the incidence of disseminated cryptococ-cal infection. (Abstract). Presented at the 31st Annual Meet¬ing of the Infectious Diseases Society of America, New Orleans, Louisiana, October 1993.
174. Farley MM, Rimland D, Baughman WS, et al. Association of culture negative cryptococcal disease with fluconazole usage in AIDS patients. (Abstract). 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, October 1993.
175. Powderly WG, Finkelstein DM, Feinberg J, et al. A random-ized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with ad-vanced human immunodeficiency virus infection. N Engl J Med 1995;332:700-5.
176. Devi SJN, Schneerson R, Egan W, et al. Cryptococcus neo-formans serotype A glucuronoxylomannan-protein conjugate vaccines: synthesis, characterization, and immunogenicity. Infect Immun 1991;59:3700-7.
177. Williamson PR, Bennett JE, Polis MA, et al. Immunogenicity and safety of a conjugate glucuronoxylomannan-tetanus con¬jugate vaccine in volunteers. (Abstract). Presented at the 31st Annual Meeting of the Infectious Diseases Society of Amer¬ica, New Orleans, Louisiana, October 1993.
178. Maslow JN, Mulligan ME, Arbeit RD. Molecular epi-demiology: application of contemporary techniques to the typing of microorganisms. Clin Infect Dis 1993;17:153-64.
179. Eisenstein BI. New molecular techniques for microbial epi¬demiology and the diagnosis of infectious diseases. J Infect Dis 1990;161:595-602.
180. Wilson DE, Bennett JE, Bailey JW. Serologic grouping of Cryptococcus neoformans. Proc Soc Exp Biol Med 1968; 127:820-3.
181. Turner SH, Cherniak R, Reiss E, et al. Structural variability in the glucuronoxylomannan of Cryptococcus neoformans serotype A isolates determined by C NMR spectroscopy. Carbohydr Res 1992;233:205-18.
182. Safrin RE, Lancaster LA, Davis CE, et al. Differentiation of Cryptococcus neoformans serotypes by isoenzyme electro-phoresis. Am J Clin Pathol 1986;86:204-8.
183. Brandt ME, Bragg SL, Pinner RW. Multilocus enzyme typ¬ing of Cryptococcus neoformans. J Clin Microbiol 1993;31: 2819-23.
184. Brandt ME, Hutwagner LC, Kuykendall RJ, et al. Compar¬ison of multilocus enzyme electrophoresis and random am¬plified polymorphic DNA analysis for molecular subtyping of Cryptococcus neoformans. J Clin Microbiol 1995, 33: 1890-5.
185. Selander RK, Musser JM, Caugant DA, et al. Population genetics of pathogenic bacteria. Microb Pathog 1987;3:1-7.
186. Polacheck I, Lebens G, Hicks JB. Development of DNA probes for early diagnosis and epidemiological study of cryptococcosis in AIDS patients. J Clin Microbiol 1992;30: 925-30.
187. Scherer S, Stevens DA. A Candida albicans dispersed, re-peated gene family and its epidemiologic applications. Proc Epidemiol Rev Vol. 17, No. 2, 1995
188. Spitzer ED, Spitzer SG. Use of a dispersed repetitive DNA element to distinguish clinical isolates of Cryptococcus neo¬formans. J Clin Microbiol 1992;30:1094-7.
189. Varma A, Kwon-Chung KJ. DNA probe for strain typing of Cryptococcus neoformans. J Clin Microbiol 1992;30: 2960-7.
190. Casadevall A, Freundlich LF, Marsh L, et al. Extensive allelic variation in Cryptococcus neoformans. J Clin Micro-biol 1992;30:1080-4.
191. Restrepo BI, Barbour AG. Cloning of 18S and 25S rDNAs from the pathogenic fungus Cryptococcus neoformans. J Bacteriol 1989;171:5596-600.
192. El-Nakhal H, Phaff HJ. Possible relationship between yeast deoxyribonucleases and deoxyribonucleic acid yield. Appl Env Microbiol 1981;41:1482-3.
193. Vilgalys R, Hester M. Rapid genetic identification and map¬ping of enzymatically amplified ribosoraal DNA from sev-eral Cryptococcus species. J Bacteriol 1990;172:4238-46.
194. Magee BB, D’Souza TM, Magee PT. Strain and species identification by restriction fragment length polymorphisms in the ribosomal DNA repeat of Candida species. J Bacteriol 1987;169:1639-43.
195. Stull TL, LiPuma JJ, Edlind TD. A broad-spectrum probe for molecular epidemiology of bacteria: ribosomal RNA. J Infect Dis 1988;157:280-6.
196. Meyer W, Mitchell TG, Freedman EZ, et al. Hybridization probes for conventional DNA fingerprinting used as single primers in the polymerase chain reaction to distinguish strains of Cryptococcus neoformans. J Clin Microbiol 1993; 31:2274-80.
197. Varma A, Kwon-Chung KJ. Restriction fragment polymor¬phism in mitochondrial DNA of Cryptococcus neoformans. J Gen Microbiol 1989; 135(part 12):3353-62.
198. Polacheck I, Lebens GA. Electrophoretic karyotype of the pathogenic yeast Cryptococcus neoformans. J Gen Microbiol 1989;135(part 1):65-71.
199. Perfect JR, Magee BB, Magee PT. Separation of chromo¬somes of Cryptococcus neoformans by pulsed field gel elec-trophoresis. Infect Immun 1989;57:2624-7.
200. Perfect JR, Ketabchi N, Cox GM, et al. Karyotyping of Cryptococcus neoformans as an epidemiological tool. J Clin Microbiol 1993;31:3305-9.
201. Spitzer ED, Spitzer SG, Freundlich LF, et al. Persistence of initial infection in recurrent Cryptococcus neoformans men¬ingitis. Lancet 1993;341:595-6.
202. Currie BP, Freundlich LF, Casadevall A. Restriction fragment length polymorphism analysis of Cryptococcus neoformans isolates from environmental pigeon excreta and clinical sources in New York City. J Clin Microbiol 1994; 32:1188-92.
203. Dromer F, Varma A, Ronin O, et al. Molecular typing of Cryptococcus neoformans serotype D clinical isolates. J Clin Microbiol 1994;32:2364-71.